Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05717920 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)
A Phase 2 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT05717920 is a Phase 2 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT05717920, a Phase 2 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.
Interventions
- DRUG ADX-629 (Open-label)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-02-15 |
| Est. Completion | 2023-11-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05717920
The ClinicalTrials.gov registry entry for NCT05717920 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADX-629 (Open-label) is the first listed.
NCT05717920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05717920 about?
NCT05717920 is a clinical study titled "A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)". A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.
What is the current status of trial NCT05717920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2023-02-15. Estimated completion is 2023-11-21.
What interventions are being tested in trial NCT05717920?
The interventions under investigation include: ADX-629 (Open-label) (DRUG).
Who is sponsoring clinical trial NCT05717920?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.